Literature DB >> 11494169

A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease.

R C Read1, J Pullin, S Gregory, R Borrow, E B Kaczmarski, F S di Giovine, S K Dower, C Cannings, A G Wilson.   

Abstract

Human Toll-like receptor 4 (TLR4) transduces proinflammatory cytokine release by human cells in response to lipopolysaccharide (LPS). This study tested the hypothesis that, if TLR4 is rate limiting for a successful response to bacterial LPS in humans, a human gene polymorphism that results in the amino acid substitution Asp299Gly and causes reduced expression and function of TLR4 should influence susceptibility to or severity of natural gram-negative infection. The allele frequency of the Asp299Gly polymorphism was 5.9% among 879 blood donors, 6.5% among 1047 patients with microbiologically proven meningococcal disease, and 4.1% among 86 patients who died of meningococcal disease. No significant differences were observed, including those analyzed after stratification of the infected population by age and by meningococcal serogroup. Therefore, this functional TLR4 polymorphism does not influence susceptibility to or severity of meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494169     DOI: 10.1086/322798

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

Review 1.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 2.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

Review 3.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  TLR4 mutations (Asp299Gly and Thr399Ile) are not associated with ankylosing spondylitis.

Authors:  R Adam; R D Sturrock; J A Gracie
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

5.  Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria.

Authors:  Frank P Mockenhaupt; Jakob P Cramer; Lutz Hamann; Miriam S Stegemann; Jana Eckert; Na-Ri Oh; Rowland N Otchwemah; Ekkehart Dietz; Stephan Ehrhardt; Nicolas W J Schröder; Ulrich Bienzle; Ralf R Schumann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

Review 6.  Genetics of innate immunity and UTI susceptibility.

Authors:  Bryndís Ragnarsdóttir; Nataliya Lutay; Jenny Grönberg-Hernandez; Bela Köves; Catharina Svanborg
Journal:  Nat Rev Urol       Date:  2011-07-12       Impact factor: 14.432

Review 7.  Toll-like receptors in defense and damage of the central nervous system.

Authors:  Rajagopal N Aravalli; Phillip K Peterson; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-04-03       Impact factor: 4.147

8.  Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility.

Authors:  Irina Smirnova; Navjiwan Mann; Annemiek Dols; H H Derkx; Martin L Hibberd; Michael Levin; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

9.  Association of gastric disease with polymorphisms in the inflammatory-related genes IL-1B, IL-1RN, IL-10, TNF and TLR4.

Authors:  Gwen Murphy; Jacinta Thornton; Ross McManus; Niall Swan; Barbara Ryan; David J Hughes; Colm A O'Morain; Maria O'Sullivan
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 2.566

10.  Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis.

Authors:  David S. Stephens; Shanta M. Zimmer
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.